2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine (CAS: 98608-59-4) is a synthetic opioid analgesic drug that belongs to the class of benzoimidazolones. The drug has gained popularity in recent years among recreational drug users due to its potent analgesic effects. However, its use carries significant risks, including potential overdose and respiratory depression. 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine has not been approved for medical use by any regulatory agency.
Chemical name
The chemical name for 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is N-(2-methyl-phenyl)-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2-amine hydrochloride.
Molecular formula
The molecular formula for 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is C20H25N3·HCl.
Formula weight
The formula weight for 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is 355.89 g/mol.
CAS No.
The CAS number for 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is 98608-59-4.
Top Ten Keywords from Google and Synonyms
Health Benefits of This Product
2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine has no known health benefits and is not approved for medical use by any regulatory agency. It is classified as a research chemical or novel psychoactive substance and is primarily used for recreational purposes.
Potential Effects
The effects of 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine on humans are not well understood, as the drug has not been extensively studied in clinical trials. The drug is reported to produce potent analgesic effects similar to other opioids, including pain relief, relaxation, and feelings of euphoria. However, there have been reports of adverse effects such as respiratory depression, sedation, and addiction at higher doses. The onset of effects is rapid, with peak effects occurring within 30-60 minutes of ingestion. The duration of effects can last up to several hours.
Product Mechanism
The mechanism of action of 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine on humans is not well understood, but it is believed to work by binding to mu-opioid receptors in the brain and spinal cord. These receptors are responsible for regulating the transmission of signals between neurons and play a critical role in pain perception, reward, and addiction. By enhancing their activity, 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine produces potent analgesic effects.
Safety
As 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine has not been approved for medical use by any regulatory agency, there is limited information on its safety profile. The drug's potential side effects and long-term effects on the brain are not well understood, and its use carries a high risk of adverse effects.
Side Effects
Common side effects of opioid drugs include nausea, vomiting, constipation, dizziness, and sedation. In some cases, these drugs can cause respiratory depression, leading to coma or even death. Overdose can occur easily with this drug, especially if used in larger amounts or in combination with other central nervous system depressants, such as alcohol or benzodiazepines. Chronic use of opioids can lead to physical dependence and addiction.
Dosing Information
Due to the lack of regulation and standardization, dosing information for 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is highly variable and often inaccurate. Users should exercise extreme caution when using this drug and start with small doses to gauge their tolerance. A typical dose of 2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine ranges from 10-50 milligrams, with a maximum daily dose of 100 milligrams. However, due to the drug's high potency, even small amounts can cause adverse effects and potential overdose.
Conclusion
2-methyl AP-237 hydrochloride AP237 HCL Bucinnazine is a synthetic compound that belongs to the class of benzoimidazolones. The drug has gained popularity in recent years among recreational drug users due to its potent
